Latest Insider Transactions at Neurocrine Biosciences Inc (NBIX)
This section provides a real-time view of insider transactions for Neurocrine Biosciences Inc (NBIX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NEUROCRINE BIOSCIENCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NEUROCRINE BIOSCIENCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 10
2025
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
457
-8.81%
|
$61,695
$135.0 P/Share
|
|
Jul 10
2025
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
457
+8.1%
|
$36,103
$79.02 P/Share
|
|
Jul 09
2025
|
Jude Onyia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
59,819
-76.59%
|
$7,776,470
$130.46 P/Share
|
|
Jul 09
2025
|
Jude Onyia Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
59,819
+43.37%
|
$5,024,796
$84.74 P/Share
|
|
Jul 02
2025
|
Jude Onyia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,362
-52.68%
|
$2,647,060
$130.13 P/Share
|
|
Jul 02
2025
|
Jude Onyia Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,362
+34.5%
|
$1,710,408
$84.74 P/Share
|
|
May 27
2025
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
9,613
-1.83%
|
$1,153,560
$120.38 P/Share
|
|
May 22
2025
|
William H Rastetter Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,869
+6.64%
|
-
|
|
May 22
2025
|
Christine A Poon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,435
+50.0%
|
-
|
|
May 22
2025
|
Stephen A Sherwin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,869
+17.48%
|
-
|
|
May 22
2025
|
Shalini Sharp Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,435
+37.14%
|
-
|
|
May 22
2025
|
George J Morrow Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,869
+28.87%
|
-
|
|
May 22
2025
|
Richard F Pops Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,869
+7.68%
|
-
|
|
May 22
2025
|
Gary A Lyons Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,435
+1.18%
|
-
|
|
May 22
2025
|
Johanna Mercier Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,435
+28.87%
|
-
|
|
May 22
2025
|
Leslie V Norwalk Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,435
+37.14%
|
-
|
|
May 16
2025
|
Julie Cooke Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,468
+19.41%
|
$394,548
$61.82 P/Share
|
|
May 05
2025
|
William H Rastetter Director |
SELL
Open market or private sale
|
Direct |
30,000
-44.45%
|
$3,300,000
$110.2 P/Share
|
|
May 05
2025
|
William H Rastetter Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+30.77%
|
$1,260,000
$42.76 P/Share
|
|
Feb 14
2025
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
500
-1.38%
|
$57,500
$115.04 P/Share
|
|
Feb 13
2025
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,551
-3.76%
|
$179,916
$116.79 P/Share
|
|
Feb 13
2025
|
Julie Cooke Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,910
+6.59%
|
-
|
|
Feb 13
2025
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
5,844
-0.56%
|
$677,904
$116.69 P/Share
|
|
Feb 13
2025
|
Kevin Charles Gorman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,979
+1.03%
|
-
|
|
Feb 13
2025
|
Stephen A Sherwin Director |
SELL
Open market or private sale
|
Direct |
13,831
-56.44%
|
$1,604,396
$116.69 P/Share
|
|
Feb 13
2025
|
Eiry Roberts Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,605
+4.12%
|
-
|
|
Feb 13
2025
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,718
-2.43%
|
$199,288
$116.82 P/Share
|
|
Feb 13
2025
|
Jude Onyia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,879
-7.62%
|
$333,964
$116.79 P/Share
|
|
Feb 13
2025
|
Jude Onyia Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,407
+12.52%
|
-
|
|
Feb 13
2025
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,184
-2.48%
|
$253,344
$116.76 P/Share
|
|
Feb 13
2025
|
Darin Lippoldt Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,100
+4.45%
|
-
|
|
Feb 13
2025
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,558
-0.91%
|
$296,728
$116.85 P/Share
|
|
Feb 13
2025
|
Kyle Gano Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,807
+1.68%
|
-
|
|
Feb 13
2025
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
1,471
-14.34%
|
$170,636
$116.71 P/Share
|
|
Feb 13
2025
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,759
+21.2%
|
-
|
|
Feb 13
2025
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
1,785
-21.98%
|
$207,060
$116.74 P/Share
|
|
Feb 13
2025
|
David W. Boyer Chief Corp. Affairs Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,352
+29.09%
|
-
|
|
Feb 13
2025
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,558
-3.5%
|
$296,728
$116.86 P/Share
|
|
Feb 13
2025
|
Matt Abernethy Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,807
+6.17%
|
-
|
|
Feb 13
2025
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,154
-2.38%
|
$249,864
$116.72 P/Share
|
|
Feb 13
2025
|
Eric Benevich Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,044
+4.27%
|
-
|
|
Feb 12
2025
|
Darin Lippoldt Chief Legal Officer |
SELL
Bona fide gift
|
Direct |
190
-0.46%
|
-
|
|
Feb 10
2025
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
700
-3.58%
|
$82,600
$118.28 P/Share
|
|
Feb 10
2025
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
2,274
-0.44%
|
$268,332
$118.37 P/Share
|
|
Feb 10
2025
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
980
-2.86%
|
$115,640
$118.22 P/Share
|
|
Feb 10
2025
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
700
-25.95%
|
$82,600
$118.31 P/Share
|
|
Feb 10
2025
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
980
-0.71%
|
$115,640
$118.39 P/Share
|
|
Feb 10
2025
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
911
-2.14%
|
$107,498
$118.25 P/Share
|
|
Feb 10
2025
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
980
-2.84%
|
$115,640
$118.27 P/Share
|
|
Feb 10
2025
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
980
-2.24%
|
$115,640
$118.31 P/Share
|